UNSPSC 51362006: Flurazepam hydrochloride

This classification denotes a benzodiazepine with the molecular formula C21H23ClFN3O.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 756RDM536M, chemically known as 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1h-1,4-benzodiazepin-2(3h)-one but more generally known as flurazepam dihydrochloride, which bears US NIH Compound Identifier 3393. European Medicines Agency schedules Flurazepam hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02238MIG.

UNSPSC 51362006 Flurazepam hydrochloride is a Commodity code that encompasses prescription pharmaceutical products supplied to state and local government health and human services agencies, though the recent state and local solicitations tagged to this code show limited direct activity for the specific compound and instead reflect broader pharmaceutical procurement patterns across the state and local sector. State and local governments soliciting under this code family are acquiring generic pharmaceuticals, over-the-counter products, and emergency response medications (including naloxone and drug deactivation systems) through a mix of county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Issuing bodies range from individual county governments to statewide cooperative purchasing entities coordinating procurement across multiple jurisdictions and participating states, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving as a notable repeat aggregator for pharmaceutical contracts across state and local government facilities.

Recent activity clusters in Florida and Minnesota, with preliminary market-intelligence procurement in Texas. Seminole County, Florida issued IFB 60459723LAS (response deadline July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 (response deadline March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed to state and local government facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026, and requiring compliance with cGMP and the Drug Supply Chain Security Act. The Texas Health and Human Services Commission issued RFI HHS0017013 (response deadline April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling early-stage state interest in alternative pharmacy benefit distribution models outside traditional pharmacy benefit manager and wholesaler channels.